Cargando…

Effect of Sodium Zirconium Cyclosilicate on Serum Potassium and Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease: Rationale and Design of the NEUTRALIZE Study

INTRODUCTION: Sodium zirconium cyclosilicate (SZC) is a selective potassium (K(+)) binder for hyperkalemia management that provides rapid and sustained correction of hyperkalemia. The NEUTRALIZE study is investigating whether SZC, in addition to correcting hyperkalemia and maintaining normal serum K...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ash, Stephen R., Batlle, Daniel, Kendrick, Jessica, Oluwatosin, Yemisi, Pottorf, William, Brahmbhatt, Yasmin, Guerrieri, Emily, Fried, Linda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Clinical Practice: Clinical Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808635/ https://www.ncbi.nlm.nih.gov/pubmed/35462371 http://dx.doi.org/10.1159/000523911

Ejemplares similares

Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate
por: Oshima, Akira, et al.
Publicado: (2021)

Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study
por: Agiro, Abiy, et al.
Publicado: (2023)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Effectiveness of Sodium Zirconium Cyclosilicate in Hemodialysis Patients With Severe Hyperkalemia
por: Ford, Martin, et al.
Publicado: (2021)

Impact of Sodium Zirconium Cyclosilicate Plus Renin–Angiotensin–Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study
por: Dwyer, Jamie P., et al.
Publicado: (2023)

Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Risk Factors for Rapid Recurrence of Hyperkalemia following Cessation of Sodium Zirconium Cyclosilicate
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan Bahadur, et al.
Publicado: (2021)

Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021)

A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient
por: Ash, Stephen R, et al.
Publicado: (2015)

Constipation as a Drug-Related Adverse Effect in Patients with Hyperkalemia: Sodium Zirconium Cyclosilicate versus Conventional Potassium Binders
por: Hida, Yuki, et al.
Publicado: (2023)

Compared effectiveness of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on hyperkalemia in patients with chronic kidney disease
por: Nakayama, Takashin, et al.
Publicado: (2023)

Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study
por: Agiro, Abiy, et al.
Publicado: (2023)

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia
por: Bushinsky, David A, et al.
Publicado: (2015)

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review
por: Beccari, Mario V, et al.
Publicado: (2017)

Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose–response, phase 2/3 study
por: Kashihara, Naoki, et al.
Publicado: (2020)

Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure
por: Tardif, Jean‐Claude, et al.
Publicado: (2022)

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]
Publicado: (2019)

Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2018)

Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis
por: Zhang, Yaru, et al.
Publicado: (2021)

A Real-World Experience of Hyperkalemia Management Using Sodium Zirconium Cyclosilicate in Chronic Hemodialysis: A Multicenter Clinical Audit
por: Qu, XiaoJie, et al.
Publicado: (2023)

Correction to: Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2019)

Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials
por: Roger, Simon D, et al.
Publicado: (2020)

Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease
por: Burton, James O, et al.
Publicado: (2023)

Erratum to: Sodium Zirconium Cyclosilicate Increases Serum Bicarbonate Concentrations Among Patients with Hyperkalaemia: Exploratory Analyses from Three Randomized, Multi-Dose, Placebo-Controlled Trials
por: Roger, Simon D, et al.
Publicado: (2020)

A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia
por: Kashihara, Naoki, et al.
Publicado: (2020)

Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
por: Rosano, Giuseppe M C, et al.
Publicado: (2019)

Hypokalemia Events With Sodium Zirconium Cyclosilicate and Placebo in Hemodialysis Patients
por: Fishbane, Steven, et al.
Publicado: (2022)

Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patients
por: Spinowitz, Bruce, et al.
Publicado: (2021)

In-hospital mortality, length of stay, and hospitalization cost of COVID-19 patients with and without hyperkalemia
por: Amin, Alpesh, et al.
Publicado: (2022)

Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE
por: Fishbane, Steven, et al.
Publicado: (2022)

Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study
por: Någård, Mats, et al.
Publicado: (2020)

Successful Conversion from Conventional Potassium Binder to Sodium Zirconium Cyclosilicate in a Patient with Refractory Constipation
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Sodium zirconium cyclosilicate pretreatment for formula in vitro reduces potassium intake in infants with chronic kidney disease
por: Liu, Boxuan, et al.
Publicado: (2022)

Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden
por: Kim, Kun, et al.
Publicado: (2022)

Phase I Study of the Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in Healthy Chinese Adults
por: Cheung, Tommy, et al.
Publicado: (2022)

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Sodium zirconium cyclosilicate (ZS-9) treatment in patients with serum potassium >6.5 mEq/L
por: Rasmussen, Henrik
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i0qgr8i6itt3j1ram19kp9r0fc